Hikma Pharmaceuticals USA Inc. announced on Friday the approval of sugammaDEX sodium for the intravenous treatment of hyperkalemia, securing a key FDA ANDA to expand its critical care portfolio. This market-moving development leverages high-barrier barriers to entry to solidify Hikma’s position as a leading supplier of life-saving anesthetic reversal agents amid current supply constraints.